Effective 1 de octubre de 2018, the BCBSRI Pharmacy Formulary will be updated to remove the generic equivalent versions for Adderall XR and Concerta from the formulary. Amphetamine/Dextroamphetamine mixed salts and Methylphenidate HCL ER will be designated as non-formulary.

All members who have existing use of the generic product received a notification letter with information suggesting use of the brand version product, which is available at a preferred brand copayment. Any member with an existing authorization for use of the generic will not be impacted by this formulary update. Notifications were distributed to the members on 1 de agosto de 2018.

While the brand version has been the preferred formulary product previously, many members are being dispensed the generic version due to pharmacy substitution practices and are paying a higher out-of-pocket expense than necessary.